Edition:
India

Arena Pharmaceuticals Inc (ARNA.OQ)

ARNA.OQ on NASDAQ Stock Exchange Global Select Market

30.59USD
2:29am IST
Change (% chg)

$0.36 (+1.19%)
Prev Close
$30.23
Open
$30.44
Day's High
$30.89
Day's Low
$30.26
Volume
93,771
Avg. Vol
179,212
52-wk High
$32.17
52-wk Low
$11.30

Chart for

About

Arena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the... (more)

Overall

Beta: 1.42
Market Cap(Mil.): $1,019.33
Shares Outstanding(Mil.): 39.22
Dividend: --
Yield (%): --

Financials

BRIEF-Arena Pharma, Everest Medicines Enter Into Development And Commercialization Partnership For Ralinepag And Etrasimod In China

* ARENA PHARMACEUTICALS AND EVEREST MEDICINES ENTER INTO DEVELOPMENT AND COMMERCIALIZATION PARTNERSHIP FOR RALINEPAG AND ETRASIMOD IN CHINA

05 Dec 2017

BRIEF-Arena Pharmaceuticals reports Q3 loss per share $0.86

* Arena Pharmaceuticals provides corporate update and reports third quarter 2017 financial results

08 Nov 2017

BRIEF-Arena Pharmaceuticals Q2 loss per share $0.77

* Arena Pharmaceuticals provides corporate update and reports second quarter 2017 financial results

08 Aug 2017

BRIEF-Arena Pharmaceuticals says public offering of 6.25 mln common shares priced at $24 per share

* Arena Pharmaceuticals announces pricing of public offering of common stock

13 Jul 2017

BRIEF-Arena Pharmaceuticals announces proposed public offering of common stock

* Arena Pharmaceuticals announces proposed public offering of common stock

12 Jul 2017

Arena's heart-lung drug succeeds in mid-stage study, shares soar

U.S. drug developer Arena Pharmaceuticals Inc said on Monday its experimental drug for pulmonary arterial hypertension (PAH), a rare but deadly lung disease, met the main goal in a mid-stage study.

11 Jul 2017

Competitors

Earnings vs. Estimates